Abstract
Discovered in 1997, PTEN remains one of the most studied tumor suppressors. In this issue of Methods in Molecular Biology, we assembled a series of papers describing various clinical and experimental approaches to studying PTEN function. Due to its broad expression, regulated subcellular localization, and intriguing phosphatase activity, methodologies aimed at PTEN study have often been developed in the context of mutations affecting various aspects of its regulation, found in patients burdened with PTEN loss-driven tumors. PTEN’s extensive posttranslational modifications and dynamic localization pose unique challenges for studying PTEN features in isolation and necessitate considerable development of experimental systems to enable controlled characterization. Nevertheless, ongoing efforts towards the development of PTEN knockout and knock-in animals and cell lines, antibodies, and enzymatic assays have facilitated a huge body of work, which continues to unravel the fascinating biology of PTEN.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Li J et al (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275(5308):1943–1947
Steck PA et al (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15(4):356–362
Bostrom J et al (1998) Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q. Cancer Res 58(1):29–33
Liu W et al (1997) PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. Cancer Res 57(23):5254–5257
Rasheed BK et al (1997) PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res 57(19):4187–4190
Dahia PL et al (1997) Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res 57(21):4710–4713
Teng DH et al (1997) MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 57(23):5221–5225
Guldberg P et al (1997) Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma. Cancer Res 57(17):3660–3663
Saal LH et al (2008) Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet 40(1):102–107
Liaw D et al (1997) Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16(1):64–67
Marsh DJ et al (1998) Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet 7(3):507–515
Eng C (1998) Genetics of Cowden syndrome: through the looking glass of oncology. Int J Oncol 12(3):701–710
Gupta A, Dey CS (2012) PTEN, a widely known negative regulator of insulin/PI3K signaling, positively regulates neuronal insulin resistance. Mol Biol Cell 23(19):3882–3898
Haas-Kogan D, Stokoe D (2008) PTEN in brain tumors. Expert Rev Neurother 8(4):599–610
Domanskyi A et al (2011) Pten ablation in adult dopaminergic neurons is neuroprotective in Parkinson’s disease models. FASEB J 25(9):2898–2910
Spinelli L et al (2015) Functionally distinct groups of inherited PTEN mutations in autism and tumour syndromes. J Med Genet 52(2):128–134
Redfern RE et al (2010) A mutant form of PTEN linked to autism. Protein Sci 19(10):1948–1956
Alonso A et al (2004) Protein tyrosine phosphatases in the human genome. Cell 117(6):699–711
Myers MP et al (1997) P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci U S A 94(17):9052–9057
Maehama T, Dixon JE (1998) The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273(22):13375–13378
Myers MP et al (1998) The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci U S A 95(23):13513–13518
Davidson L et al (2010) Suppression of cellular proliferation and invasion by the concerted lipid and protein phosphatase activities of PTEN. Oncogene 29(5):687–697
Stambolic V et al (1998) Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95(1):29–39
Manning BD, Cantley LC (2007) AKT/PKB signaling: navigating downstream. Cell 129(7):1261–1274
Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2(7):489–501
Engelman JA, Luo J, Cantley LC (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7(8):606–619
Li DM, Sun H (1997) TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res 57(11):2124–2129
Poon JS, Eves R, Mak AS (2010) Both lipid- and protein-phosphatase activities of PTEN contribute to the p53-PTEN anti-invasion pathway. Cell Cycle 9(22):4450–4454
Trotman LC et al (2007) Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell 128(1):141–156
Fouladkou F et al (2008) The ubiquitin ligase Nedd4-1 is dispensable for the regulation of PTEN stability and localization. Proc Natl Acad Sci U S A 105(25):8585–8590
Wang X et al (2007) NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 128(1):129–139
Tibarewal P et al (2012) PTEN protein phosphatase activity correlates with control of gene expression and invasion, a tumor-suppressing phenotype, but not with AKT activity. Sci Signal 5(213):ra18
Liliental J et al (2000) Genetic deletion of the Pten tumor suppressor gene promotes cell motility by activation of Rac1 and Cdc42 GTPases. Curr Biol 10(7):401–404
Zhang XC et al (2012) Functional analysis of the protein phosphatase activity of PTEN. Biochem J 444(3):457–464
Williams R, Masson G, Vadas O, Burke J, Perisic O (2015) Structural mechanisms of PI3K and PTEN regulation. FASEB J 29(1):1–6
Bolduc D et al (2013) Phosphorylation-mediated PTEN conformational closure and deactivation revealed with protein semisynthesis. Elife 2:e00691
Tang Y, Eng C (2006) p53 down-regulates phosphatase and tensin homologue deleted on chromosome 10 protein stability partially through caspase-mediated degradation in cells with proteasome dysfunction. Cancer Res 66(12):6139–6148
Han B et al (2003) Regulation of constitutive expression of mouse PTEN by the 5′-untranslated region. Oncogene 22(34):5325–5337
Stambolic V et al (2001) Regulation of PTEN transcription by p53. Mol Cell 8(2):317–325
Tamguney T, Stokoe D (2007) New insights into PTEN. J Cell Sci 120(Pt 23):4071–4079
Garcia JM et al (2004) Promoter methylation of the PTEN gene is a common molecular change in breast cancer. Genes Chromosomes Cancer 41(2):117–124
Goel A et al (2004) Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res 64(9):3014–3021
Kang YH, Lee HS, Kim WH (2002) Promoter methylation and silencing of PTEN in gastric carcinoma. Lab Invest 82(3):285–291
Poliseno L, Pandolfi PP (2015) PTEN ceRNA networks in human cancer. Methods 77–78C:41–50
Vazquez F et al (2000) Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol 20(14):5010–5018
Al-Khouri AM et al (2005) Cooperative phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein kinases and glycogen synthase kinase 3beta. J Biol Chem 280(42):35195–35202
Cordier F et al (2012) Ordered phosphorylation events in two independent cascades of the PTEN C-tail revealed by NMR. J Am Chem Soc 134(50):20533–20543
Cordier F, Chaffotte A, Wolff N (2015) Quantitative and dynamic analysis of PTEN phosphorylation by NMR. Methods 77–78:82–91
Fragoso R, Barata JT (2015) Kinases, tails and more: regulation of PTEN function by phosphorylation. Methods 77–78:75–81
Vemula S et al (2010) ROCK1 functions as a suppressor of inflammatory cell migration by regulating PTEN phosphorylation and stability. Blood 115(9):1785–1796
Okumura K et al (2006) PCAF modulates PTEN activity. J Biol Chem 281(36):26562–26568
Kwon J et al (2004) Reversible oxidation and inactivation of the tumor suppressor PTEN in cells stimulated with peptide growth factors. Proc Natl Acad Sci U S A 101(47):16419–16424
Wang X et al (2008) Crucial role of the C-terminus of PTEN in antagonizing NEDD4-1-mediated PTEN ubiquitination and degradation. Biochem J 414(2):221–229
Bar N, Dikstein R (2010) miR-22 forms a regulatory loop in PTEN/AKT pathway and modulates signaling kinetics. PLoS One 5(5):e10859
Li N et al (2015) Poly-ADP ribosylation of PTEN by tankyrases promotes PTEN degradation and tumor growth. Genes Dev 29(2):157–170
Lee JO et al (1999) Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell 99(3):323–334
Huang J et al (2012) SUMO1 modification of PTEN regulates tumorigenesis by controlling its association with the plasma membrane. Nat Commun 3:911
Naguib A et al (2015) PTEN functions by recruitment to cytoplasmic vesicles. Mol Cell 58(2):255–268
Perren A et al (1999) Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 155(4):1253–1260
Mutter GL et al (2000) Changes in endometrial PTEN expression throughout the human menstrual cycle. J Clin Endocrinol Metab 85(6):2334–2338
Perren A et al (2000) Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am J Pathol 157(4):1097–1103
Deleris P et al (2003) SHIP-2 and PTEN are expressed and active in vascular smooth muscle cell nuclei, but only SHIP-2 is associated with nuclear speckles. J Biol Chem 278(40):38884–38891
Gimm O et al (2000) Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am J Pathol 156(5):1693–1700
Tachibana M et al (2002) Expression and prognostic significance of PTEN product protein in patients with esophageal squamous cell carcinoma. Cancer 94(7):1955–1960
Whiteman DC et al (2002) Nuclear PTEN expression and clinicopathologic features in a population-based series of primary cutaneous melanoma. Int J Cancer 99(1):63–67
Fridberg M et al (2007) Protein expression and cellular localization in two prognostic subgroups of diffuse large B-cell lymphoma: higher expression of ZAP70 and PKC-beta II in the non-germinal center group and poor survival in patients deficient in nuclear PTEN. Leuk Lymphoma 48(11):2221–2232
Lindsay Y et al (2006) Localization of agonist-sensitive PtdIns(3,4,5)P3 reveals a nuclear pool that is insensitive to PTEN expression. J Cell Sci 119(Pt 24):5160–5168
Bassi C et al (2013) Nuclear PTEN controls DNA repair and sensitivity to genotoxic stress. Science 341(6144):395–399
Dedes KJ et al (2010) PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Transl Med 2(53):53ra75
McEllin B et al (2010) PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer Res 70(13):5457–5464
Mendes-Pereira AM et al (2009) Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 1(6–7):315–322
Hopkins BD et al (2013) A secreted PTEN phosphatase that enters cells to alter signaling and survival. Science 341(6144):399–402
Liang H et al (2014) PTENalpha, a PTEN isoform translated through alternative initiation, regulates mitochondrial function and energy metabolism. Cell Metab 19(5):836–848
Li Y et al (2014) Rab5 and Ndfip1 are involved in Pten ubiquitination and nuclear trafficking. Traffic 15(7):749–761
Pulido R et al (2014) A unified nomenclature and amino acid numbering for human PTEN. Sci Signal 7(332):pe15
Acknowledgements
The work in the authors’ laboratory is supported by the funds from the Canadian Institutes of Health Research and the Canadian Cancer Society. OG is supported by the Excellence in Radiation Research for the 21st century (EIRR21st) postdoctoral fellowship.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this protocol
Cite this protocol
Gorbenko, O., Stambolic, V. (2016). PTEN at 18: Still Growing. In: Salmena, L., Stambolic, V. (eds) PTEN. Methods in Molecular Biology, vol 1388. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3299-3_2
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3299-3_2
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-3297-9
Online ISBN: 978-1-4939-3299-3
eBook Packages: Springer Protocols